Sonelokimab
M1095-PSA-303
Phase 3 small_molecule active
Quick answer
Sonelokimab for psoriatic arthritis (PsA) is a Phase 3 program (small_molecule) at MoonLake Immunotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- MoonLake Immunotherapeutics
- Indication
- psoriatic arthritis (PsA)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active